ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1346

Predicting Major Treatment Response to Tumor Necrosis Factor Inhibitorsin Patients with Ankylosing Spondylitis

Runsheng Wang1, Abhijit Dasgupta2 and Michael Ward3, 1Columbia University Irving Medical Center, Division of Rheumatology, New York, NY, 2NIAMS, Bethesda, 3National Institutes of Health, Bethesda, MD

Meeting: ACR Convergence 2020

Keywords: Ankylosing spondylitis (AS), comparative effectiveness, TNF-blocking Antibody

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Session Title: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The treatment response to tumor necrosis factor inhibitors (TNFi) in patients with active ankylosing spondylitis (AS) is heterogeneous.  In clinical practice, both patients and clinicians are interested to know how likely a patient will achieve a major response after initiating TNFi.  The objective of this study is to develop a predictive model for a favorable response to TNFi based on baseline clinical features in patients with active AS.

Methods: We obtained individual patient data from randomized clinical trials of Adalimumab and Etanercept in active AS, and aggregated the participant data in the TNFi arms for a pooled analysis.  The main outcome was major response at week 12, defined by achieving Ankylosing Spondylitis Assessment 40% (ASAS40) response.  Baseline characteristics including age, sex, body mass index (BMI), disease duration, spondyloarthritis features, C-reactive protein (CRP), HLA-B27 positivity, and patient reported outcomes were included as predictors.  The entire cohort was split by 5:1 for model development and validation.  We used Random Forest algorithm to develop the predictive model with ranking of the importance of features, and the performance was examined using receiver operating characteristics area under the curve (ROC – AUC).  The process was repeated independently for 5 times, and the final AUC was the average.

Results: A total of six RCTs of Adalimumab or Etanercept in patients with active AS were identified, and 1090 subjects who were in the TNFi arms were eligible and included in the analysis.  Baseline characteristics are summarized in Table 1.  Average age was 38.7 +/-  11.7 years, 75.3% were male patients, and 85.5% were HLA-B27 positive.  Fifty-one percent of subjects achieved ASAS40 response at week 12.  The Random Forest models had a small to medium effect with average AUC of 0.66 (Figure 1).  At baseline, higher CRP level, worse night pain, younger age, worse patient global assessment, and lower BMI were the most important features that predicted a major response.

Conclusion: Using Random Forest algorithm, we developed a model to predict treatment response to TNFi in patients with active AS.  Preliminary analysis showed a small to medium effect with AUC of 0.66.  At baseline, higher CRP, worse night pain, younger age, worse patient global assessment, and lower BMI are the most important features in the prediction model.

Table 1. Baseline characteristics of eligible subjects. SD: standard deviation; SpA: spondyloarthritis; BASDAI: Bath ankylosing spondylitis disease activity index; BASFI: Bath ankylosing spondylitis functional index; ASAS40: Assessment of SpondyloArthritis International Society (ASAS) 40% response criteria.

Figure 1. Performance of Random Forest Models in testing set using Receiver Operating Characteristic curves. ROC: receiver operating characteristic; AUC: area under the curve.


Disclosure: R. Wang, Eli Lilly, 1, Novartis, 1; A. Dasgupta, None; M. Ward, None.

To cite this abstract in AMA style:

Wang R, Dasgupta A, Ward M. Predicting Major Treatment Response to Tumor Necrosis Factor Inhibitorsin Patients with Ankylosing Spondylitis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/predicting-major-treatment-response-to-tumor-necrosis-factor-inhibitorsin-patients-with-ankylosing-spondylitis/. Accessed April 1, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predicting-major-treatment-response-to-tumor-necrosis-factor-inhibitorsin-patients-with-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences